Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration

To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD). Multicenter, prospective, randomized, double-masked clinical trial with initial 12-week fi...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 118; číslo 6; s. 1089
Hlavní autori:	Brown, David M, Heier, Jeffrey S, Ciulla, Thomas, Benz, Matthew, Abraham, Prema, Yancopoulos, George, Stahl, Neil, Ingerman, Avner, Vitti, Robert, Berliner, Alyson J, Yang, Ke, Nguyen, Quan Dong
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.06.2011
Predmet:	Aged Aged, 80 and over Choroidal Neovascularization - diagnosis Choroidal Neovascularization - etiology Choroidal Neovascularization - prevention & control Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Fovea Centralis - drug effects Fovea Centralis - pathology Humans Intravitreal Injections Male Middle Aged Prospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - administration & dosage Vascular Endothelial Growth Factor A - therapeutic use Visual Acuity Wet Macular Degeneration - complications Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
ISSN:	1549-4713, 1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!